RxBio

Executive Summary

RxBio Inc. is a privately held biotechnology company based in Johnson City, Tennessee, founded in 2008. The company specializes in developing medical countermeasures and vaccines against infectious diseases and biodefense threats, addressing critical public health and national security needs. With a focus on advanced biomedical research, RxBio aims to provide solutions for emerging pathogens and biological threats, leveraging its expertise in vaccine and therapeutic development. Although the company has not publicly disclosed financials or late-stage pipeline assets, its niche focus on biodefense positions it as a potential partner for government agencies like BARDA or NIH. RxBio’s long-standing presence in the field since 2008 suggests a sustained commitment to this challenging area, though details on product candidates and clinical progress remain limited.

Upcoming Catalysts (preview)

• Q4 2026Government Contract or Grant Award for Biodefense Vaccine Development60% success
• Q1 2027Announcement of Preclinical Data for Lead Vaccine Candidate50% success
• Q2 2027Strategic Partnership or Licensing Agreement with Larger Pharma35% success